France· FR:66578108
CASGEVY 4 à 13 x 1 000 000 cellules/mL, dispersion pour perfusion
A exagamglogene autotemcel product containing exagamglogène autotemcel, registered in France by VERTEX PHARMACEUTICALS (EUROPE) LIMITED. The same ATC class is registered in 12 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Exagamglogene autotemcel is registered in 12 of 19 countries.
Countries holding a registration under ATC B06AX05 (exagamglogene autotemcel), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Exagamglogene autotemcel · ATC B06AX05
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- EXAGAMGLOGÈNE AUTOTEMCEL
- Manufacturer
- VERTEX PHARMACEUTICALS (EUROPE) LIMITED
- Country
- France (FR)
- ATC code
- B06AX05
- ATC class
- Exagamglogene autotemcel
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550995741 ou plusieurs flacons copolymère de cyclooléfines (COC) de 1.5 mL à 20 mL. Spécifique au patient.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Exagamglogene autotemcel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCASGEVYVertex Pharmaceuticals Incorporated
- SwitzerlandCasgevy 4-13 x 10e6 cells/ml, InfusionsdispersionVertex Pharmaceuticals (CH) GmbH
- CzechiaCASGEVYVertex Pharmaceuticals (Ireland) Limited, Dublin
- SpainCASGEVY 4 - 13 × 10E6 CELULAS/ML DISPERSION PARA PERFUSIONVertex Pharmaceuticals (Ireland) Limited
- FinlandCasgevyVertex Pharmaceuticals (Ireland) Limited
- United KingdomCasgevy 4million-13million cells/ml dispersion for infusion vialsVertex Pharmaceuticals (Europe) Ltd
- BelgiumCasgevy 4 10*6 cells/ml - 13 10*6 cells/mlVertex Pharmaceuticals (Ireland)
- IcelandCasgevyVertex Pharmaceuticals (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Casgevy
- Liechtenstein · Casgevy
- Norway · Casgevy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2dba8752-9b11-4af2-a434-924c2036ff90 GET /v1/drugs/2dba8752-9b11-4af2-a434-924c2036ff90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66578108",
"date_amm": "2024-02-09",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1787",
"substance": "EXAGAMGLOGÈNE AUTOTEMCEL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "dispersion pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about exagamglogene autotemcel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.